We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
GSK has entered into an exclusive agreement with Chongqing Zhifei Biological Products to jointly promote GSK’s shingles vaccine, Shingrix, in China for an initial three-year period, with the
Sharp, a provider of commercial pharmaceutical packaging and clinical trial supply services, has acquired Berkshire Sterile Manufacturing (BSM), a contract development and manufacturing organisation (CDMO) for an undisclosed
Shorla Oncology, a US-Ireland speciality pharmaceutical company, has disclosed a successful Series B funding round, securing a substantial $35m in investment. This funding round was spearheaded by Kurma
Capsida Biotherapeutics and Kate Therapeutics have entered into a strategic partnership to tap into Capsida’s proficiency in adeno-associated virus (AAV) manufacturing. The collaboration aims to facilitate KateTx’s initial
Clade Therapeutics has acquired Gadeta, a company specialising in innovative gamma/delta (g/d) T-cell receptor (TCR)-based immunotherapies for cancer patients. Gadeta’s proprietary platform enables the engineering of unique g/d
Kyverna Therapeutics, a clinical-stage cell therapy company, has entered into a non-exclusive, multi-year licence and supply agreement with Oxford Biomedica, a viral vector contract and development manufacturing organisation
Merck has revealed two strategic collaborations in drug discovery that leverage the capabilities of artificial intelligence (AI) for design and discovery. These partnerships involve BenevolentAI based in London,
The European Commission has approved ViiV Healthcare’s Apretude (cabotegravir long-acting (LA) injectable and tablets) to prevent HIV (human immunodeficiency virus). ViiV Healthcare is the specialist HIV company majority
Traverse Biotech, a US-based biotechnology firm, has entered into a license agreement with Genmab under which Traverse will develop and commercialise a bispecific antibody designed for cancer immunotherapy.
Moderna and Immatics, a clinical-stage biopharmaceutical company specialising in the discovery and development of T cell-redirecting cancer immunotherapies, have announced a strategic research and development collaboration. The partnership